The abstract is read at the publisher; the summary is JClub's.
Precision psychiatry aligns drug development with neural-biology dysfunctions using biomarkers, leveraging patient-specific brain and peripheral measures to stratify patients and predict treatment response.
- Why it matters: Symptom-based diagnosis has slowed therapeutic advances, so a biology-linked framework is needed to better match interventions to underlying dysfunction and reduce development risk.
- What they did: The Perspective draws lessons from precision oncology and neurology, using biomarkers such as electroencephalography, objective behavioral tests, functional magnetic resonance imaging, and peripheral biomarkers to study drug effects and stratify populations.
- The result: Proof-of-concept examples, including predictors of response to standard-of-care treatments and subgroup-driven successes in postpartum depression and schizophrenia, support stratified trials and scalable biomarker integration for improved outcomes.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.